Key Points
- Insider sale: Tango Therapeutics insider Adam Crystal sold 27,000 shares on June 1 for about $617,490 at an average price of $22.87. After the sale, he still held 115,743 shares, a decrease of 18.92% in his position.
- Recent selling trend: This was one of several recent stock sales by Crystal, including multiple transactions in March, April, and May. The repeated sales total a meaningful reduction in his stake over the past few months.
- Company/stock snapshot: TNGX was trading around $21.47, near its 50-day average of $22.39 and below its 12-month high of $28.41. The company recently reported earnings of -$0.32 per share, matching expectations, while analysts currently rate the stock a Moderate Buy overall.
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 27,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $22.87, for a total value of $617,490.00. Following the transaction, the insider owned 115,743 shares in the company, valued at approximately $2,647,042.41. This trade represents a 18.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Adam Crystal also recently made the following trade(s):
- On Friday, May 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.23, for a total value of $573,210.00.
- On Wednesday, April 15th, Adam Crystal sold 38,460 shares of Tango Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $961,500.00.
- On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.20, for a total value of $572,400.00.
- On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $20.11, for a total value of $241,320.00.
- On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The shares were sold at an average price of $15.00, for a total value of $303,765.00.
Tango Therapeutics Stock Down 0.1%
Shares of TNGX stock opened at $21.47 on Thursday. Tango Therapeutics, Inc. has a 12 month low of $2.96 and a 12 month high of $28.41. The business's 50 day moving average is $22.39 and its two-hundred day moving average is $15.48. The company has a market cap of $3.11 billion, a PE ratio of -25.87 and a beta of 1.19.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32). Tango Therapeutics had a negative return on equity of 41.54% and a negative net margin of 151.15%. As a group, equities analysts expect that Tango Therapeutics, Inc. will post -1.33 EPS for the current fiscal year.
Institutional Investors Weigh In On Tango Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Legal & General Group Plc boosted its stake in shares of Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company's stock valued at $36,000 after purchasing an additional 1,640 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Tango Therapeutics by 26.7% in the 4th quarter. Russell Investments Group Ltd. now owns 9,794 shares of the company's stock valued at $87,000 after purchasing an additional 2,065 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Tango Therapeutics by 52.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company's stock valued at $58,000 after purchasing an additional 2,243 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Tango Therapeutics by 10.2% in the 1st quarter. SG Americas Securities LLC now owns 24,257 shares of the company's stock valued at $507,000 after purchasing an additional 2,251 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Tango Therapeutics by 0.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company's stock valued at $10,237,000 after purchasing an additional 2,272 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company's stock.
Analyst Ratings Changes
TNGX has been the topic of several analyst reports. Piper Sandler downgraded Tango Therapeutics from an "overweight" rating to a "neutral" rating and increased their price target for the company from $16.00 to $24.00 in a report on Thursday, May 14th. UBS Group set a $55.00 price objective on shares of Tango Therapeutics in a research note on Thursday, May 14th. HC Wainwright raised their price objective on shares of Tango Therapeutics from $13.00 to $27.00 and gave the stock a "buy" rating in a research note on Friday, March 6th. Leerink Partners raised their price objective on shares of Tango Therapeutics from $28.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday, May 14th. Finally, Citigroup restated a "buy" rating on shares of Tango Therapeutics in a research note on Monday, April 27th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $32.27.
View Our Latest Stock Report on Tango Therapeutics
Tango Therapeutics Company Profile
(
Get Free Report)
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
